- ROUNDTABLE: Pharmacy’s future in sync with technology
- Study from NCPA sheds new light on med synchronization programs
- Coalition of healthcare industry stakeholders address best practices regarding controlled substances
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
ORLANDO, Fla. — The Generic Pharmaceutical Association on Wednesday announced that Craig Wheeler, president and CEO, Momenta Pharmaceuticals, was elected as GPhA board chairman. Wheeler succeeds Tony Mauro, president, Mylan North America.
“I’m honored to be elected as chairman of GPhA’s board of directors,” Wheeler said. “Our member companies provide timely access to safe and affordable generic medicines for patients around the globe, putting treatment within reach for hundreds of millions of people. There are so many opportunities ahead for this dynamic industry, and I look forward to contributing to our shared success.”
“It is a time of extraordinary promise for our industry,” commented Ralph Neas, president and CEO of GPhA. “Patient safety remains our top priority as the Association leads efforts to preserve and promote access to generic medicines. Chairman Wheeler’s strong leadership will be pivotal as the industry works with the FDA, Congress and stakeholders at all levels of the health care system to improve labeling guidance, establish a framework for interchangeable biologic substitution, meet GDUFA goals and advocate for policies that encourage generic utilization at home and abroad.”